nodes	percent_of_prediction	percent_of_DWPC	metapath
Sodium stibogluconate—TOP1—Caspase Cascade in Apoptosis—KRT18—liver cancer	0.0928	0.247	CbGpPWpGaD
Sodium stibogluconate—TOP1—Circadian rythm related genes—SIX3—liver cancer	0.0339	0.0901	CbGpPWpGaD
Sodium stibogluconate—TOP1—Caspase Cascade in Apoptosis—TNFSF10—liver cancer	0.0257	0.0684	CbGpPWpGaD
Sodium stibogluconate—TOP1—Caspase Cascade in Apoptosis—CYCS—liver cancer	0.0235	0.0625	CbGpPWpGaD
Sodium stibogluconate—TOP1—Caspase Cascade in Apoptosis—BCL2L1—liver cancer	0.0161	0.0428	CbGpPWpGaD
Sodium stibogluconate—Faecaloma—Epirubicin—liver cancer	0.0154	0.0247	CcSEcCtD
Sodium stibogluconate—Faecalith—Epirubicin—liver cancer	0.0154	0.0247	CcSEcCtD
Sodium stibogluconate—TOP1—Integrated Pancreatic Cancer Pathway—FST—liver cancer	0.0154	0.0408	CbGpPWpGaD
Sodium stibogluconate—Faecalith—Doxorubicin—liver cancer	0.0143	0.0228	CcSEcCtD
Sodium stibogluconate—Faecaloma—Doxorubicin—liver cancer	0.0143	0.0228	CcSEcCtD
Sodium stibogluconate—Warmth—Epirubicin—liver cancer	0.0138	0.0222	CcSEcCtD
Sodium stibogluconate—Hypocalcaemia—Sorafenib—liver cancer	0.013	0.0209	CcSEcCtD
Sodium stibogluconate—Hyperphosphataemia—Epirubicin—liver cancer	0.0129	0.0207	CcSEcCtD
Sodium stibogluconate—TOP1—Circadian rythm related genes—AHR—liver cancer	0.0129	0.0342	CbGpPWpGaD
Sodium stibogluconate—Warmth—Doxorubicin—liver cancer	0.0128	0.0205	CcSEcCtD
Sodium stibogluconate—TOP1—Integrated Pancreatic Cancer Pathway—HNF4A—liver cancer	0.0119	0.0318	CbGpPWpGaD
Sodium stibogluconate—Hyperphosphataemia—Doxorubicin—liver cancer	0.0119	0.0191	CcSEcCtD
Sodium stibogluconate—TOP1—Integrated Pancreatic Cancer Pathway—HPGDS—liver cancer	0.0117	0.0311	CbGpPWpGaD
Sodium stibogluconate—TOP1—Caspase Cascade in Apoptosis—CASP3—liver cancer	0.00996	0.0265	CbGpPWpGaD
Sodium stibogluconate—Cardiac failure congestive—Sorafenib—liver cancer	0.00954	0.0153	CcSEcCtD
Sodium stibogluconate—Renal failure acute—Sorafenib—liver cancer	0.00937	0.015	CcSEcCtD
Sodium stibogluconate—Hyponatraemia—Sorafenib—liver cancer	0.00868	0.0139	CcSEcCtD
Sodium stibogluconate—Hypernatraemia—Epirubicin—liver cancer	0.00837	0.0134	CcSEcCtD
Sodium stibogluconate—Venous thrombosis—Epirubicin—liver cancer	0.00816	0.0131	CcSEcCtD
Sodium stibogluconate—Dehydration—Sorafenib—liver cancer	0.00804	0.0129	CcSEcCtD
Sodium stibogluconate—Hypokalaemia—Sorafenib—liver cancer	0.00787	0.0126	CcSEcCtD
Sodium stibogluconate—Hypernatraemia—Doxorubicin—liver cancer	0.00775	0.0124	CcSEcCtD
Sodium stibogluconate—TOP1—Integrated Pancreatic Cancer Pathway—ABL1—liver cancer	0.0077	0.0205	CbGpPWpGaD
Sodium stibogluconate—Venous thrombosis—Doxorubicin—liver cancer	0.00755	0.0121	CcSEcCtD
Sodium stibogluconate—Dysphagia—Sorafenib—liver cancer	0.00747	0.012	CcSEcCtD
Sodium stibogluconate—TOP1—Caspase Cascade in Apoptosis—TNF—liver cancer	0.00725	0.0193	CbGpPWpGaD
Sodium stibogluconate—TOP1—Integrated Pancreatic Cancer Pathway—PCNA—liver cancer	0.0066	0.0176	CbGpPWpGaD
Sodium stibogluconate—Acute coronary syndrome—Sorafenib—liver cancer	0.00657	0.0105	CcSEcCtD
Sodium stibogluconate—Renal failure—Sorafenib—liver cancer	0.00655	0.0105	CcSEcCtD
Sodium stibogluconate—Myocardial infarction—Sorafenib—liver cancer	0.00653	0.0105	CcSEcCtD
Sodium stibogluconate—Lung disorder—Epirubicin—liver cancer	0.00622	0.00997	CcSEcCtD
Sodium stibogluconate—TOP1—Circadian rythm related genes—PPARA—liver cancer	0.00602	0.016	CbGpPWpGaD
Sodium stibogluconate—TOP1—Integrated Pancreatic Cancer Pathway—MAPK14—liver cancer	0.00579	0.0154	CbGpPWpGaD
Sodium stibogluconate—Lung disorder—Doxorubicin—liver cancer	0.00576	0.00922	CcSEcCtD
Sodium stibogluconate—TOP1—Integrated Pancreatic Cancer Pathway—ESR1—liver cancer	0.00568	0.0151	CbGpPWpGaD
Sodium stibogluconate—Feeling hot—Epirubicin—liver cancer	0.00561	0.00899	CcSEcCtD
Sodium stibogluconate—Necrosis—Epirubicin—liver cancer	0.00561	0.00899	CcSEcCtD
Sodium stibogluconate—Abscess—Epirubicin—liver cancer	0.00556	0.00892	CcSEcCtD
Sodium stibogluconate—TOP1—Caspase Cascade in Apoptosis—AKT1—liver cancer	0.00539	0.0143	CbGpPWpGaD
Sodium stibogluconate—TOP1—Integrated Pancreatic Cancer Pathway—APC—liver cancer	0.00537	0.0143	CbGpPWpGaD
Sodium stibogluconate—Arrhythmia—Sorafenib—liver cancer	0.00534	0.00857	CcSEcCtD
Sodium stibogluconate—Feeling hot—Doxorubicin—liver cancer	0.00519	0.00832	CcSEcCtD
Sodium stibogluconate—Necrosis—Doxorubicin—liver cancer	0.00519	0.00832	CcSEcCtD
Sodium stibogluconate—Abscess—Doxorubicin—liver cancer	0.00515	0.00825	CcSEcCtD
Sodium stibogluconate—Dysgeusia—Sorafenib—liver cancer	0.0051	0.00817	CcSEcCtD
Sodium stibogluconate—Extravasation—Epirubicin—liver cancer	0.00505	0.00809	CcSEcCtD
Sodium stibogluconate—TOP1—Circadian rythm related genes—PPARG—liver cancer	0.00498	0.0132	CbGpPWpGaD
Sodium stibogluconate—Cellulitis—Epirubicin—liver cancer	0.00484	0.00776	CcSEcCtD
Sodium stibogluconate—Hypocalcaemia—Epirubicin—liver cancer	0.00481	0.00771	CcSEcCtD
Sodium stibogluconate—Oliguria—Epirubicin—liver cancer	0.00478	0.00766	CcSEcCtD
Sodium stibogluconate—Syncope—Sorafenib—liver cancer	0.00467	0.00748	CcSEcCtD
Sodium stibogluconate—Extravasation—Doxorubicin—liver cancer	0.00467	0.00748	CcSEcCtD
Sodium stibogluconate—Ulcer—Epirubicin—liver cancer	0.00465	0.00746	CcSEcCtD
Sodium stibogluconate—Creatinine increased—Epirubicin—liver cancer	0.00463	0.00741	CcSEcCtD
Sodium stibogluconate—Loss of consciousness—Sorafenib—liver cancer	0.00458	0.00734	CcSEcCtD
Sodium stibogluconate—TOP1—Circadian rythm related genes—SERPINE1—liver cancer	0.00448	0.0119	CbGpPWpGaD
Sodium stibogluconate—Cellulitis—Doxorubicin—liver cancer	0.00448	0.00718	CcSEcCtD
Sodium stibogluconate—Hypocalcaemia—Doxorubicin—liver cancer	0.00445	0.00713	CcSEcCtD
Sodium stibogluconate—Oliguria—Doxorubicin—liver cancer	0.00442	0.00708	CcSEcCtD
Sodium stibogluconate—Ulcer—Doxorubicin—liver cancer	0.00431	0.0069	CcSEcCtD
Sodium stibogluconate—Creatinine increased—Doxorubicin—liver cancer	0.00428	0.00686	CcSEcCtD
Sodium stibogluconate—Anaphylactic shock—Sorafenib—liver cancer	0.00425	0.00681	CcSEcCtD
Sodium stibogluconate—Infection—Sorafenib—liver cancer	0.00422	0.00677	CcSEcCtD
Sodium stibogluconate—TOP1—Integrated Pancreatic Cancer Pathway—RAF1—liver cancer	0.00422	0.0112	CbGpPWpGaD
Sodium stibogluconate—Shock—Sorafenib—liver cancer	0.00418	0.0067	CcSEcCtD
Sodium stibogluconate—Fluid retention—Epirubicin—liver cancer	0.00418	0.0067	CcSEcCtD
Sodium stibogluconate—Blood urea increased—Epirubicin—liver cancer	0.00416	0.00666	CcSEcCtD
Sodium stibogluconate—Anorexia—Sorafenib—liver cancer	0.00405	0.00649	CcSEcCtD
Sodium stibogluconate—Fluid retention—Doxorubicin—liver cancer	0.00387	0.0062	CcSEcCtD
Sodium stibogluconate—TOP1—Integrated Pancreatic Cancer Pathway—CDKN1B—liver cancer	0.00386	0.0103	CbGpPWpGaD
Sodium stibogluconate—Blood urea increased—Doxorubicin—liver cancer	0.00385	0.00616	CcSEcCtD
Sodium stibogluconate—Sepsis—Epirubicin—liver cancer	0.00382	0.00612	CcSEcCtD
Sodium stibogluconate—Dyspnoea—Sorafenib—liver cancer	0.00379	0.00607	CcSEcCtD
Sodium stibogluconate—TOP1—Integrated Pancreatic Cancer Pathway—CASP3—liver cancer	0.00379	0.0101	CbGpPWpGaD
Sodium stibogluconate—Phlebitis—Epirubicin—liver cancer	0.00371	0.00595	CcSEcCtD
Sodium stibogluconate—Decreased appetite—Sorafenib—liver cancer	0.00369	0.00592	CcSEcCtD
Sodium stibogluconate—TOP1—Integrated Pancreatic Cancer Pathway—CCND1—liver cancer	0.00369	0.0098	CbGpPWpGaD
Sodium stibogluconate—TOP1—Integrated Pancreatic Cancer Pathway—JUN—liver cancer	0.00368	0.00978	CbGpPWpGaD
Sodium stibogluconate—Fatigue—Sorafenib—liver cancer	0.00366	0.00587	CcSEcCtD
Sodium stibogluconate—TOP1—Integrated Pancreatic Cancer Pathway—CTNNB1—liver cancer	0.00365	0.00971	CbGpPWpGaD
Sodium stibogluconate—Constipation—Sorafenib—liver cancer	0.00363	0.00582	CcSEcCtD
Sodium stibogluconate—TOP1—Integrated Pancreatic Cancer Pathway—CDKN1A—liver cancer	0.00357	0.00948	CbGpPWpGaD
Sodium stibogluconate—Sepsis—Doxorubicin—liver cancer	0.00353	0.00567	CcSEcCtD
Sodium stibogluconate—TOP1—Circadian rythm related genes—JUN—liver cancer	0.00353	0.00939	CbGpPWpGaD
Sodium stibogluconate—Cardiac failure congestive—Epirubicin—liver cancer	0.00352	0.00565	CcSEcCtD
Sodium stibogluconate—TOP1—Integrated Pancreatic Cancer Pathway—MAPK8—liver cancer	0.00348	0.00926	CbGpPWpGaD
Sodium stibogluconate—Gastrointestinal pain—Sorafenib—liver cancer	0.00348	0.00557	CcSEcCtD
Sodium stibogluconate—Renal failure acute—Epirubicin—liver cancer	0.00346	0.00555	CcSEcCtD
Sodium stibogluconate—Phlebitis—Doxorubicin—liver cancer	0.00343	0.0055	CcSEcCtD
Sodium stibogluconate—Urticaria—Sorafenib—liver cancer	0.00338	0.00541	CcSEcCtD
Sodium stibogluconate—Abdominal pain—Sorafenib—liver cancer	0.00336	0.00538	CcSEcCtD
Sodium stibogluconate—Body temperature increased—Sorafenib—liver cancer	0.00336	0.00538	CcSEcCtD
Sodium stibogluconate—Renal impairment—Epirubicin—liver cancer	0.00336	0.00538	CcSEcCtD
Sodium stibogluconate—TOP1—Circadian rythm related genes—MAPK8—liver cancer	0.00334	0.00888	CbGpPWpGaD
Sodium stibogluconate—Cerebrovascular accident—Epirubicin—liver cancer	0.00326	0.00523	CcSEcCtD
Sodium stibogluconate—Cardiac failure congestive—Doxorubicin—liver cancer	0.00326	0.00523	CcSEcCtD
Sodium stibogluconate—TOP1—Integrated Pancreatic Cancer Pathway—VEGFA—liver cancer	0.00321	0.00855	CbGpPWpGaD
Sodium stibogluconate—Hyponatraemia—Epirubicin—liver cancer	0.00321	0.00514	CcSEcCtD
Sodium stibogluconate—Renal failure acute—Doxorubicin—liver cancer	0.0032	0.00513	CcSEcCtD
Sodium stibogluconate—Hypersensitivity—Sorafenib—liver cancer	0.00313	0.00502	CcSEcCtD
Sodium stibogluconate—Renal impairment—Doxorubicin—liver cancer	0.00311	0.00498	CcSEcCtD
Sodium stibogluconate—Asthenia—Sorafenib—liver cancer	0.00305	0.00489	CcSEcCtD
Sodium stibogluconate—Cerebrovascular accident—Doxorubicin—liver cancer	0.00302	0.00484	CcSEcCtD
Sodium stibogluconate—Pruritus—Sorafenib—liver cancer	0.00301	0.00482	CcSEcCtD
Sodium stibogluconate—Blood creatinine increased—Epirubicin—liver cancer	0.00299	0.0048	CcSEcCtD
Sodium stibogluconate—Dehydration—Epirubicin—liver cancer	0.00297	0.00476	CcSEcCtD
Sodium stibogluconate—Hyponatraemia—Doxorubicin—liver cancer	0.00297	0.00476	CcSEcCtD
Sodium stibogluconate—TOP1—Integrated Pancreatic Cancer Pathway—MYC—liver cancer	0.00296	0.00786	CbGpPWpGaD
Sodium stibogluconate—TOP1—Integrated Pancreatic Cancer Pathway—TGFB1—liver cancer	0.00295	0.00784	CbGpPWpGaD
Sodium stibogluconate—Hypokalaemia—Epirubicin—liver cancer	0.00291	0.00466	CcSEcCtD
Sodium stibogluconate—Diarrhoea—Sorafenib—liver cancer	0.00291	0.00466	CcSEcCtD
Sodium stibogluconate—Dizziness—Sorafenib—liver cancer	0.00281	0.0045	CcSEcCtD
Sodium stibogluconate—Abdominal distension—Epirubicin—liver cancer	0.00278	0.00446	CcSEcCtD
Sodium stibogluconate—Blood creatinine increased—Doxorubicin—liver cancer	0.00277	0.00444	CcSEcCtD
Sodium stibogluconate—Dysphagia—Epirubicin—liver cancer	0.00276	0.00443	CcSEcCtD
Sodium stibogluconate—TOP1—Integrated Pancreatic Cancer Pathway—TNF—liver cancer	0.00275	0.00732	CbGpPWpGaD
Sodium stibogluconate—Dehydration—Doxorubicin—liver cancer	0.00275	0.00441	CcSEcCtD
Sodium stibogluconate—TOP1—Integrated Pancreatic Cancer Pathway—KRAS—liver cancer	0.00273	0.00726	CbGpPWpGaD
Sodium stibogluconate—Vomiting—Sorafenib—liver cancer	0.0027	0.00433	CcSEcCtD
Sodium stibogluconate—Hypokalaemia—Doxorubicin—liver cancer	0.00269	0.00431	CcSEcCtD
Sodium stibogluconate—Rash—Sorafenib—liver cancer	0.00268	0.00429	CcSEcCtD
Sodium stibogluconate—Dermatitis—Sorafenib—liver cancer	0.00268	0.00429	CcSEcCtD
Sodium stibogluconate—Headache—Sorafenib—liver cancer	0.00266	0.00427	CcSEcCtD
Sodium stibogluconate—Bronchitis—Epirubicin—liver cancer	0.00266	0.00426	CcSEcCtD
Sodium stibogluconate—Abdominal distension—Doxorubicin—liver cancer	0.00257	0.00412	CcSEcCtD
Sodium stibogluconate—Dysphagia—Doxorubicin—liver cancer	0.00256	0.0041	CcSEcCtD
Sodium stibogluconate—Nausea—Sorafenib—liver cancer	0.00252	0.00405	CcSEcCtD
Sodium stibogluconate—TOP1—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	0.00251	0.00667	CbGpPWpGaD
Sodium stibogluconate—Bronchitis—Doxorubicin—liver cancer	0.00246	0.00394	CcSEcCtD
Sodium stibogluconate—TOP1—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	0.00243	0.00646	CbGpPWpGaD
Sodium stibogluconate—Renal failure—Epirubicin—liver cancer	0.00242	0.00388	CcSEcCtD
Sodium stibogluconate—TOP1—Circadian rythm related genes—TP53—liver cancer	0.00233	0.0062	CbGpPWpGaD
Sodium stibogluconate—Renal failure—Doxorubicin—liver cancer	0.00224	0.00359	CcSEcCtD
Sodium stibogluconate—Hypoaesthesia—Epirubicin—liver cancer	0.0022	0.00353	CcSEcCtD
Sodium stibogluconate—TOP1—Circadian rythm related genes—IL6—liver cancer	0.00213	0.00567	CbGpPWpGaD
Sodium stibogluconate—TOP1—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	0.00205	0.00545	CbGpPWpGaD
Sodium stibogluconate—Hypoaesthesia—Doxorubicin—liver cancer	0.00204	0.00326	CcSEcCtD
Sodium stibogluconate—Arrhythmia—Epirubicin—liver cancer	0.00198	0.00317	CcSEcCtD
Sodium stibogluconate—Flatulence—Epirubicin—liver cancer	0.0019	0.00304	CcSEcCtD
Sodium stibogluconate—Dysgeusia—Epirubicin—liver cancer	0.00188	0.00302	CcSEcCtD
Sodium stibogluconate—Arrhythmia—Doxorubicin—liver cancer	0.00183	0.00293	CcSEcCtD
Sodium stibogluconate—Vision blurred—Epirubicin—liver cancer	0.00181	0.00291	CcSEcCtD
Sodium stibogluconate—Flatulence—Doxorubicin—liver cancer	0.00175	0.00281	CcSEcCtD
Sodium stibogluconate—Dysgeusia—Doxorubicin—liver cancer	0.00174	0.00279	CcSEcCtD
Sodium stibogluconate—Syncope—Epirubicin—liver cancer	0.00173	0.00277	CcSEcCtD
Sodium stibogluconate—Palpitations—Epirubicin—liver cancer	0.0017	0.00273	CcSEcCtD
Sodium stibogluconate—Loss of consciousness—Epirubicin—liver cancer	0.00169	0.00271	CcSEcCtD
Sodium stibogluconate—Vision blurred—Doxorubicin—liver cancer	0.00168	0.00269	CcSEcCtD
Sodium stibogluconate—Convulsion—Epirubicin—liver cancer	0.00167	0.00267	CcSEcCtD
Sodium stibogluconate—Chest pain—Epirubicin—liver cancer	0.00164	0.00263	CcSEcCtD
Sodium stibogluconate—Anxiety—Epirubicin—liver cancer	0.00163	0.00262	CcSEcCtD
Sodium stibogluconate—Syncope—Doxorubicin—liver cancer	0.0016	0.00256	CcSEcCtD
Sodium stibogluconate—Palpitations—Doxorubicin—liver cancer	0.00157	0.00252	CcSEcCtD
Sodium stibogluconate—Anaphylactic shock—Epirubicin—liver cancer	0.00157	0.00252	CcSEcCtD
Sodium stibogluconate—Oedema—Epirubicin—liver cancer	0.00157	0.00252	CcSEcCtD
Sodium stibogluconate—Loss of consciousness—Doxorubicin—liver cancer	0.00157	0.00251	CcSEcCtD
Sodium stibogluconate—Infection—Epirubicin—liver cancer	0.00156	0.0025	CcSEcCtD
Sodium stibogluconate—Shock—Epirubicin—liver cancer	0.00155	0.00248	CcSEcCtD
Sodium stibogluconate—Convulsion—Doxorubicin—liver cancer	0.00154	0.00247	CcSEcCtD
Sodium stibogluconate—Tachycardia—Epirubicin—liver cancer	0.00153	0.00246	CcSEcCtD
Sodium stibogluconate—Hyperhidrosis—Epirubicin—liver cancer	0.00152	0.00243	CcSEcCtD
Sodium stibogluconate—Chest pain—Doxorubicin—liver cancer	0.00152	0.00243	CcSEcCtD
Sodium stibogluconate—Anxiety—Doxorubicin—liver cancer	0.00151	0.00242	CcSEcCtD
Sodium stibogluconate—Anorexia—Epirubicin—liver cancer	0.0015	0.0024	CcSEcCtD
Sodium stibogluconate—Hypotension—Epirubicin—liver cancer	0.00147	0.00235	CcSEcCtD
Sodium stibogluconate—Anaphylactic shock—Doxorubicin—liver cancer	0.00145	0.00233	CcSEcCtD
Sodium stibogluconate—Oedema—Doxorubicin—liver cancer	0.00145	0.00233	CcSEcCtD
Sodium stibogluconate—Infection—Doxorubicin—liver cancer	0.00144	0.00231	CcSEcCtD
Sodium stibogluconate—Shock—Doxorubicin—liver cancer	0.00143	0.00229	CcSEcCtD
Sodium stibogluconate—Tachycardia—Doxorubicin—liver cancer	0.00142	0.00227	CcSEcCtD
Sodium stibogluconate—Paraesthesia—Epirubicin—liver cancer	0.00141	0.00226	CcSEcCtD
Sodium stibogluconate—Hyperhidrosis—Doxorubicin—liver cancer	0.00141	0.00225	CcSEcCtD
Sodium stibogluconate—Dyspnoea—Epirubicin—liver cancer	0.0014	0.00224	CcSEcCtD
Sodium stibogluconate—Anorexia—Doxorubicin—liver cancer	0.00139	0.00222	CcSEcCtD
Sodium stibogluconate—Decreased appetite—Epirubicin—liver cancer	0.00137	0.00219	CcSEcCtD
Sodium stibogluconate—Hypotension—Doxorubicin—liver cancer	0.00136	0.00218	CcSEcCtD
Sodium stibogluconate—Fatigue—Epirubicin—liver cancer	0.00135	0.00217	CcSEcCtD
Sodium stibogluconate—Constipation—Epirubicin—liver cancer	0.00134	0.00215	CcSEcCtD
Sodium stibogluconate—Paraesthesia—Doxorubicin—liver cancer	0.00131	0.00209	CcSEcCtD
Sodium stibogluconate—Dyspnoea—Doxorubicin—liver cancer	0.0013	0.00208	CcSEcCtD
Sodium stibogluconate—Gastrointestinal pain—Epirubicin—liver cancer	0.00128	0.00206	CcSEcCtD
Sodium stibogluconate—Decreased appetite—Doxorubicin—liver cancer	0.00126	0.00202	CcSEcCtD
Sodium stibogluconate—Fatigue—Doxorubicin—liver cancer	0.00125	0.00201	CcSEcCtD
Sodium stibogluconate—Urticaria—Epirubicin—liver cancer	0.00125	0.002	CcSEcCtD
Sodium stibogluconate—Constipation—Doxorubicin—liver cancer	0.00124	0.00199	CcSEcCtD
Sodium stibogluconate—Body temperature increased—Epirubicin—liver cancer	0.00124	0.00199	CcSEcCtD
Sodium stibogluconate—Abdominal pain—Epirubicin—liver cancer	0.00124	0.00199	CcSEcCtD
Sodium stibogluconate—Gastrointestinal pain—Doxorubicin—liver cancer	0.00119	0.0019	CcSEcCtD
Sodium stibogluconate—Hypersensitivity—Epirubicin—liver cancer	0.00116	0.00185	CcSEcCtD
Sodium stibogluconate—Urticaria—Doxorubicin—liver cancer	0.00115	0.00185	CcSEcCtD
Sodium stibogluconate—Body temperature increased—Doxorubicin—liver cancer	0.00115	0.00184	CcSEcCtD
Sodium stibogluconate—Abdominal pain—Doxorubicin—liver cancer	0.00115	0.00184	CcSEcCtD
Sodium stibogluconate—Asthenia—Epirubicin—liver cancer	0.00113	0.00181	CcSEcCtD
Sodium stibogluconate—Pruritus—Epirubicin—liver cancer	0.00111	0.00178	CcSEcCtD
Sodium stibogluconate—Diarrhoea—Epirubicin—liver cancer	0.00107	0.00172	CcSEcCtD
Sodium stibogluconate—Hypersensitivity—Doxorubicin—liver cancer	0.00107	0.00172	CcSEcCtD
Sodium stibogluconate—Asthenia—Doxorubicin—liver cancer	0.00104	0.00167	CcSEcCtD
Sodium stibogluconate—Dizziness—Epirubicin—liver cancer	0.00104	0.00166	CcSEcCtD
Sodium stibogluconate—Pruritus—Doxorubicin—liver cancer	0.00103	0.00165	CcSEcCtD
Sodium stibogluconate—Vomiting—Epirubicin—liver cancer	0.000999	0.0016	CcSEcCtD
Sodium stibogluconate—Diarrhoea—Doxorubicin—liver cancer	0.000994	0.00159	CcSEcCtD
Sodium stibogluconate—Rash—Epirubicin—liver cancer	0.00099	0.00159	CcSEcCtD
Sodium stibogluconate—Dermatitis—Epirubicin—liver cancer	0.000989	0.00159	CcSEcCtD
Sodium stibogluconate—Headache—Epirubicin—liver cancer	0.000984	0.00158	CcSEcCtD
Sodium stibogluconate—Dizziness—Doxorubicin—liver cancer	0.000961	0.00154	CcSEcCtD
Sodium stibogluconate—Nausea—Epirubicin—liver cancer	0.000933	0.0015	CcSEcCtD
Sodium stibogluconate—Vomiting—Doxorubicin—liver cancer	0.000924	0.00148	CcSEcCtD
Sodium stibogluconate—Rash—Doxorubicin—liver cancer	0.000916	0.00147	CcSEcCtD
Sodium stibogluconate—Dermatitis—Doxorubicin—liver cancer	0.000916	0.00147	CcSEcCtD
Sodium stibogluconate—Headache—Doxorubicin—liver cancer	0.00091	0.00146	CcSEcCtD
Sodium stibogluconate—Nausea—Doxorubicin—liver cancer	0.000863	0.00138	CcSEcCtD
